Google DeepMind and Meta Join Biohub's $1.8 Billion AI Biology Push

Summary

Alphabet (GOOGL) and Meta Platforms (META) are buying into AI biology. On Wednesday, October 7, Google DeepMind, Alphabet’s drug discovery unit Isomorphic Labs, and Meta agreed to put a combined $300 million into Biohub’s Virtual Biology Initiative. Biohub is the science group backed by Mark Zuckerberg and Priscilla Chan. With the U.S. Department of Energy and the National Institutes of Health also in, total commitments now reach $1.8 billion. What the Money Buys The initiative will measure how cells respond across far more conditions than scientists have ever tested, then use that data to train AI models that predict cell behavior. The first dataset is due in about a year, and the goal is accurate predictive models within five. The funding breaks down like this: - Biohub: $500 million, committed in April - Department of Energy: more than $500 million over five years - NIH: more than $500 million in earlier federal funding, now being standardized for the project - Google DeepMind, Isomorphic Labs, and Meta: $300 million combined In return, the three companies see the data before the public does. Commercial funders get a one-year embargo on the data they help pay for, while government-funded data has none. “We have to have some incentive for commercial players to be a part of this, and the embargo period creates that,” Biohub head of science Alex Rives said. $300 Million Is a Rounding Error for Alphabet and Meta The check is tiny next to what these two already spend. Alphabet spent $68.97 billion on research and development over the last 12 months, and Meta spent $71.63 billion. Together that’s $140.6 billion, or about $385 million a day. So the entire $300 million commitment is less than one day of their combined research budgets. Both companies have more than doubled R&D since 2021, and Meta now outspends Alphabet. Capital spending makes the gap even wider. Alphabet spent $91.45 billion on capex in 2025 and Meta spent $69.69 billion, each roughly 3.7 times its 2021 level. Both companies have tied most of that spending to AI data centers. Biology is a small add-on to that spending. Nothing in this deal moves either company’s earnings. Why Early Access Is the Real Asset What the money really buys is time. A one-year embargo on commercially funded datasets gives participating companies a head start in training models before those datasets become public. That…